Effects of Pranlukast Hydrate on Airway Hyperresponsiveness in Non-Asthmatic Patients with Japanese Cedar Pollinosis

Sagara, Hironori; Yukawa, Tatsuo; Kashima, Ryuichi; Okada, Takenori; Fukuda, Takeshi

doi:10.2332/allergolint.08-oa-0058

Cited by 9 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38,45e47 Recently, Sagara et al showed that initial treatment with pranlukast plus mequitazine significantly suppressed exacerbation airway hyper-responsiveness during the pollen season in non-asthmatic patients with JCCP. 48 …”

Section: Pharmacotherapymentioning

confidence: 97%

Association and management of eosinophilic inflammation in upper and lower airways

Okano

Kariya

Ohta

et al. 2015

Allergology International

View full text Add to dashboard Cite

This review discussed the contribution of eosinophilic upper airway inflammation includes allergic rhinitis (AR) and chronic rhinosinusitis (CRS) to the pathophysiology and course of asthma, the representative counterpart in the lower airway. The presence of concomitant AR can affect the severity of asthma in patients who have both diseases; however, it is still debatable whether the presence of asthma affects the severity of AR. Hypersensitivity, obstruction and/or inflammation in the lower airway can be detected in patients with AR without awareness or diagnosis of asthma, and AR is known as a risk factor for the new onset of wheeze and asthma both in children and adults. Allergen immunotherapy, pharmacotherapy and surgery for AR can contribute to asthma control; however, a clear preventive effect on the new onset of asthma has been demonstrated only for immunotherapy. Pathological similarities such as epithelial shedding are also seen between asthma and CRS, especially eosinophilic CRS. Abnormal sinus findings on computed tomography are seen in the majority of asthmatic patients, and asthmatic patients with CRS show a significant impairment in Quality of Life (QOL) and pulmonary function as compared to those without CRS. Conversely, lower airway inflammation and dysfunction are seen in non-asthmatic patients with CRS. Treatments for CRS that include pharmacotherapy such as anti-leukotrienes, surgery, and aspirin desensitization show a beneficial effect on concomitant asthma. Acting as a gatekeeper of the united airways, the control of inflammation in the nose is crucial for improvement of the QOL of patients with co-existing AR/CRS and asthma.

show abstract

Section: Pharmacotherapymentioning

confidence: 97%

Association and management of eosinophilic inflammation in upper and lower airways

Okano

Kariya

Ohta

et al. 2015

Allergology International

View full text Add to dashboard Cite

show abstract

“…The effectiveness of omalizumab on AR and Japanese cedar pollinosis was demonstrated as well as on asthma. 29,30 These data suggest that certain systemic drugs such as LTRAs and anti-IgE monoclonal antibody would produce better asthma-related outcomes in patients with asthma and concomitant AR.…”

Section: Treatment Strategy Of Asthma With Comorbid Ar or Japanese Cementioning

confidence: 97%

Asthma in Patients With Japanese Cedar Pollinosis

Tanaka

Minoguchi

Pawankar

et al. 2012

World Allergy Organization Journal

View full text Add to dashboard Cite

Japanese cedar pollen is the most common causative allergen for seasonal allergic rhinitis (AR) in Japan. More commonly known as Japanese cedar pollinosis, it occurs in spring causing the typical symptoms of seasonal AR, such as sneezing, rhinorrhea, nasal obstruction, nasal itching, and itching of the eyes. Previous reports indicate that the prevalence of Japanese cedar pollinosis among Japanese was 26.5%. According to a more recent questionnaire-based survey, the prevalence of Japanese cedar pollinosis in patients with adult asthma might be up to 30% to 50%, suggesting higher rates than that previously reported. Moreover, 30% to 60% of adult asthmatic patients with concomitant pollinosis have exacerbations of their asthma symptoms during the Japanese cedar pollen season. These findings suggest that concomitant Japanese cedar pollinosis may be an aggravating factor in patients with asthma. As with other pollens, such as grass and birch, Japanese cedar pollen was shown to be a trigger factor for worsening asthma. In clinical practice, a number of Japanese patients with asthma are monosensitized to Japanese cedar pollen but not to other antigens. Further studies are needed to elucidate the mechanisms of Japanese cedar pollen in inducing and in exacerbating asthma. The presence of concomitant AR is often associated with the difficulty in asthma control. However, there has been a controversy whether treating concomitant AR by intranasal corticosteroid would produce better asthma-related outcomes in patients with asthma and AR. The effect of treating concomitant cedar pollinosis by intranasal corticosteroids on asthma control in patients with asthma and cedar pollinosis also remains unknown. Certain systemic treatments, such as leukotriene receptor antagonist and anti-IgE monoclonal antibody, are supposed to reduce the symptoms of both asthma and AR in patients with asthma and concomitant AR. In conclusion, Japanese cedar pollinosis is often associated with exacerbations of asthma. Further investigations are expected to elucidate the precise impact and mechanisms of Japanese cedar pollinosis in asthma.

show abstract

“…In several studies, pranlukast showed significant efficacy in reversing bronchoconstriction caused by various stimuli, including LTD 4 , dust mite, aspirin, exercise, and even alcohol (Abraham et Hamilton et al, 1998;Ishioka et al, 2000;Suguro et al, 2000;Yoshida et al, 2000b;Myou et al, 2001;Obase et al, 2001Obase et al, , 2002. Some other studies also showed the effectiveness of pranlukast in reducing bronchial hypersensitiveness, another important feature of asthma, caused by various factors (Nakamura et al, 1998;Ishioka et al, 2000;Yoshida et al, 2000a;Yamauchi et al, 2001;Sagara et al, 2009). Because the current first-line method for treating asthma is ICS or ICS plus LABAs, a number of recent studies tested whether pranlukast could provide additional clinical benefits when used with ICS or ICS plus LABAs.…”

Section: B Currently Used Leukotriene Receptor Antagonist Drugs and mentioning

confidence: 99%

G Protein–Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action

Wendell¹,

Fan²,

Zhang³

2019

Pharmacol Rev

View full text Add to dashboard Cite

show abstract

Effects of Pranlukast Hydrate on Airway Hyperresponsiveness in Non-Asthmatic Patients with Japanese Cedar Pollinosis

Abstract: The results indicate that pranlukast hydrate inhibits airway hyperresponsiveness in non-asthmatic patients with Japanese cedar pollinosis. In turn, this suggests that cysteinyl leukotrienes have a role in increased airway responsiveness.

Cited by 9 publications

References 18 publications

Association and management of eosinophilic inflammation in upper and lower airways

Association and management of eosinophilic inflammation in upper and lower airways

Asthma in Patients With Japanese Cedar Pollinosis

G Protein–Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action

Contact Info

Product

Resources

About